Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.1 (
alkaline phosphatase
)
47,916
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A431 human epidermoid carcinoma cells monophenotypically express the placental alkaline phosphatase (PLAP)-like enzyme shown by its catalytic and antigenic characteristics, properties which are shared by the
Nagao isozyme
. More specifically, it is L-leucine sensitive just as is the rare placental D-variant of PLAP and the testicular heat-stable enzyme. Collectively, these are all referred to as
PLAP-like
enzymes. The enzyme was localized to the surface of the plasma membrane since it was released in an active form by bromelain treatment of cells. The number of molecules per A431 cell was estimated by radioimmunoassay at 7.5 X 10(5), a value significantly higher than that observed for HeLa TCRC-1 cells (5 X 10(4) which express the S-variant of PLAP, also referred to as the Regan isozyme. The quantity of the enzyme was increased significantly (10-fold) by treating the cells with modulating agents including sodium butyrate, prednisolone, and hyperosmolar sodium chloride. The identification of a cell line such as A431 with enhanced expression in the amount of the
PLAP-like
enzyme and which can be further enhanced by modulating agents will facilitate studies of the differences and the similarities between this protein and other variants of PLAP. The A431 cell line now takes its place with other cell lines which are phenotypically restricted in their expression of
alkaline phosphatase
. Finally, the A431 cell line is also shown here to be a suitable model system for in vivo tumor studies such as immunolocalization.
...
PMID:Characterization of the placental alkaline phosphatase-like (Nagao) isozyme on the surface of A431 human epidermoid carcinoma cells. 257 98
Electrophoretic patterns of seminoma- and normal-testis-derived
alkaline phosphatase
isozymes, the placental alkaline phosphatase (PLAP)-like enzyme and the tissue-nonspecific (liver)
alkaline phosphatase
(LAP), were studied on starch gel and isoelectric focusing (IEF). Different migration patterns of the
PLAP-like
enzyme were observed with respect to both seminomas and normal testes on starch gel electrophoresis. On IEF, seminomas showed different staining patterns among different tumors; however, a common main activity was focused at pIs of 4.3-4.6, corresponding to pIs of PLAP. Normal testes showed two enzyme-staining regions, at pIs of 4.1 and 5.0-5.2, which were discriminated from pIs of PLAP and the
PLAP-like
enzyme in seminoma. The
PLAP-like
enzyme in seminoma was differentiated from PLAP by digestion with neuraminidase. Neuraminidase treatment simplified the distribution patterns of the
PLAP-like
enzyme in normal testis, but did not alter the pattern of microheterogeneity in seminoma. Two factors other than sialylation, namely structural modification of the carbohydrate moiety and variation of hydrophobicity, were shown to contribute to the microheterogeneity of the
PLAP-like
enzyme in seminoma. LAP in seminoma and in normal testis also showed marked electrophoretic heterogeneity and differences in pI distributions from LAP of liver. However, the migration patterns after desialylation were very similar to each other. The findings imply that electrophoretic heterogeneity demonstrated in LAP in seminoma and in normal testis is caused by a difference in sialic acid content in the molecule, and the heterogeneity of the
PLAP-like
enzyme in seminoma is considerable.
...
PMID:Electrophoretic heterogeneity of alkaline phosphatase isozymes in seminoma and normal testis. 278 Dec 21
In 1930 the determination of serum
alkaline phosphatase
in patients with bone or liver disease ushered in the era of clinical enzymology. The association of elevated (bone)
alkaline phosphatase
in serum of patients with osteogenic sarcoma was the first evidence that tumor cells themselves produced the enzyme. It became clear, however, in the 1960s that the serum
alkaline phosphatase
was not a single enzyme but consisted of a family of isozymes originating from liver, bone, intestine, and placenta. This was a consequence of the introduction of a combination of electrophoretic separations, heat inactivation, and organ-specific amino acid inhibitors. This combination of measurements made possible the demonstration of a serum
alkaline phosphatase
of lung cancer origin, as confirmed by the histochemical visualization in lung cancer of the Regan Isozyme (placental alkaline phosphatase-PLAP). At present, the measurement of PLAP has its greatest utility as a tumor marker in seminoma and ovarian cancer. A
PLAP-like
isozyme in normal testis and ovary is expressed in these and other neoplasias and appears to be related to rare alleles of placental alkaline phosphatase. Current studies have utilized a panel of monoclonal antibodies to detect useful epitopes that suggest that PLAP and
PLAP-like
isozymes are coded by different genes. The PLAP gene has now been cloned and sequenced by Millan and others. This fundamental new information is providing a base line that will make it possible to explain the overlapping specificities of intestinal and placental isozymes, the degree of uniqueness of the
PLAP-like
isozyme, the precise mechanism of uncompetitive inhibition by L-phenylalanine and the evolutionary history of the alkaline phosphatases.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Clinical and biological significance of an isozyme tumor marker--PLAP. 332 92
There are at least three
alkaline phosphatase
(AP) isoenzymes in man: a heat-stable placental enzyme (PLAP), a less heat-stable intestinal form (IAP), and the very heat-labile AP enriched in liver, bone and kidney. In addition to these enzymes, there is a heat-stable activity in the thymus and testis that is similar but not identical to the PLAP (the
PLAP-like
enzyme). Previous work has demonstrated a close structural relatedness among the IAP, PLAP and
PLAP-like
enzymes. Thus, it is possible that there are three human genes encoding heat-stable AP enzymes. To test this hypothesis, we have used a PLAP cDNA clone to screen a human genomic library cloned into the phage vector lambda EMBL-3. Three sets of clones were isolated, each bearing a distinct coding region homologous to the PLAP cDNA probe. Nucleotide sequence analysis of the 5' ends of these genes allowed comparison of their derived peptide sequences and positive identification of two of the genes. One of the genes encodes the PLAP (the PLAP-1 gene), another encodes the IAP, and a third closely resembles the PLAP-1 gene, but is distinct from it (the PLAP-2 gene). The PLAP-2 gene is highly homologous (greater than 95%) with the PLAP-1 except in the first exon, where sequences encoding the hydrophobic signal peptide are nearly identical with the same region of the IAP gene. These results demonstrate the existence of a small family of PLAP-related genes which is the result of at least two duplication events during the descent of man.
...
PMID:Two gene duplication events in the evolution of the human heat-stable alkaline phosphatases. 344 2
Specific assays for human intestinal and liver alkaline phosphatases were developed by use of isozyme specific monoclonal antibodies bound to paper discs. The assays are fast, specific and convenient to use as demonstrated by determinations of
alkaline phosphatase
isozymes in sera and tissues. In sera from forty healthy individuals the activity of the tissue unspecific
alkaline phosphatase
was determined to 32 +/- 12 IU/l (mean +/- SD). The activity of the intestinal alkaline phosphatase was found to be ten-fold lower, 3.5 +/- 6.3 IU/l (mean +/- SD), and of the placental alkaline phosphatase another ten-fold lower, 0.3 +/- 0.2 IU/l (mean +/- SD), than that of the tissue unspecific
alkaline phosphatase
. Several normal tissues contained all three isozymes, the intestinal mucosa, for example, which besides intestinal alkaline phosphatase also expresses trace amounts of placental and liver-bone-kidney
alkaline phosphatase
. Seminomas, known to express eutopically
placental-like alkaline phosphatase
were demonstrated to contain increased levels of both intestinal and liver-bone-kidney alkaline phosphatases as compared to the normal testis.
...
PMID:Specific assays for human alkaline phosphatase isozymes. 362 3
The three human isozymes of alkaline phosphatases were quantitatively determined in normal testis and seminoma tissues. The highly selective assays were based on isozyme specific monoclonal antibodies. In the normal testis approximately 90% of the catalytic activity originates from the tissue unspecific
alkaline phosphatase
, and the remaining activity was due to trace expression of both intestinal (approximately 5%) and placental alkaline phosphatase (PLAP) or
PLAP-like
isozyme (approximately 5%). In homogenates of seminoma tissues, highly increased levels of all three isozymes were identified. Both the tissue unspecific
alkaline phosphatase
and
PLAP-like
enzymes displayed relative increases of 10- to 100-fold and intestinal alkaline phosphatase 2- to 10-fold compared with normal testis. This finding indicates that the entire genome coding for alkaline phosphatases may be activated in seminomas. The
PLAP-like
enzyme from seminoma cells comprises a heterogenous population of molecules demonstrating partial heat sensitivity and microheterogeneity upon starch gel electrophoresis in contrast to the pregnancy related PLAP. These findings have implications for the different PLAP assays used in the clinical monitoring of seminoma patients.
...
PMID:Levels of alkaline phosphatase isozymes in human seminoma tissue. 364 91
To study the origin of increased serum
placental-like alkaline phosphatase
(
PLAP-like
) activity in smokers, heat stable
alkaline phosphatase
activity was assayed from serum and bronchoalveolar lavage (BAL) fluid in 83 smoking and non-smoking patients.
PLAP-like
activity was increased in about 80% of the smokers, independently of the underlying lung disease. Isoenzyme activities in BAL fluid correlated (r = 0.631, p less than 0.001) with serum values. When adjusted for the albumin concentration, mean
PLAP-like
activity in BAL fluid was almost 1000-fold higher than that in serum, suggesting local synthesis of
PLAP-like
isoenzymes in the lungs. Although a direct dose-response effect was not observed, the values in serum and in BAL fluid tended to be higher in patients smoking over 10 cigarettes daily as compared to patients smoking less. In ex-smokers the results indicated that
PLAP-like
activity decreased to the level observed in non-smokers within 5 years after cessation of smoking. PLAP activity was L-leucine sensitive compatible with the Nagao-variant type of PLAP in almost all cases. In three patients the activity was due to the L-leucine resistant (true placental) isoenzyme.
...
PMID:Increased serum placental-like alkaline phosphatase activity in smokers originates from the lungs. 367 17
Solid-phase enzyme immunoassays, based on monoclonal antibodies reactive with different forms of human placental-type alkaline phosphatases, were applied to their detection in human seminal plasma from fertile and infertile men. The placental-like form of
alkaline phosphatase
(
PLAP-like
AP), known to occur in testicular tissue, was found in normal seminal plasma. The incidence of detection and levels of this isoenzyme correlated significantly with the designated fertility status of the donor. Seminal plasma (
PLAP-like
AP) may reflect germ cell function and/or access of testicular products to the ejaculate.
...
PMID:Placental-type alkaline phosphatase in human seminal plasma from fertile and infertile men. 378 Oct 10
We have used a mouse monoclonal antibody (H7) to placental alkaline phosphatase (PLAP,
EC 3.1.3.1
) in developing an immunoenzymometric assay for PLAP and
PLAP-like
enzymes. The antibody is bound to sheep anti-mouse IgG (Ab2) covalently coupled to tosylated shell-and-core light (1.07 g/cm3) monodisperse polymer particles. Adding the H7-Ab2-polymer particle suspension to a PLAP-containing sample gives maximal binding of the antigen within 10 min. PLAP and
PLAP-like
enzymes remain active and bound to the solid-phase throughout all assay manipulations, and can thus be saved for future testing. In testing the enzymes for inhibition by L-Phe, L-Phe-Gly-Gly, L-Leu, and L-homoarginine, the effect of all the inhibitors is fully reversible. The assay is highly versatile, and its sensitivity (routinely 0.05 micrograms/L) can be increased 1000-fold by adjusting the sample volume and incubation time (sample volume is irrelevant between 50 microL and 5 mL). We have measured the basal activities of PLAP in men and women and, by using enzyme inhibitors, have characterized it as corresponding to the
PLAP-like
phenotypes described in normal human testis.
...
PMID:Highly sensitive solid-phase immunoenzymometric assay for placental and placental-like alkaline phosphatases with a monoclonal antibody and monodisperse polymer particles. 388 Jun 82
Monoclonal antibodies (H317 and H17E2) against placental-type
alkaline phosphatase
and testicular
placental-like alkaline phosphatase
were radiolabelled with 123I or 131I and used in a prospective study of patients with germ-cell neoplasms of the testis (13 studies) or epithelial-origin neoplasms of the ovary (13 studies). The presence of tumour was confirmed in the majority of patients with active disease by antibody scanning. The absence of tumour was confirmed in all cases in patients in complete remission. In two patients with positive antibody scans but no disease found by conventional radiological evaluation, further investigations subsequently revealed the presence of tumour. A positive antibody scan indicates the definite presence of a tumour, although a negative antibody scan does not always exclude the presence of disease. This method may be of clinical value in establishing disease status in patients with potentially curable diseases such as ovarian or testicular cancers.
...
PMID:Antibody-guided radiolocalisation of tumours in patients with testicular or ovarian cancer using two radioiodinated monoclonal antibodies to placental alkaline phosphatase. 394 19
<< Previous
1
2
3
4
Next >>